GNBT,
Generex Biotechnology Announces Expansion of Glucose RapidSpray(TM) Distribution
Tuesday October 10, 8:00 am ET
Company Fills Purchase Orders From Additional Retail Pharmacies
TORONTO--(MARKET WIRE)--Oct 10, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in metabolic diseases drug delivery through the inner lining of the mouth, announced today that it has filled several purchase orders from additional retail pharmacies for Glucose RapidSpray, its new over-the-counter glucose oral spray product.
Generex has filled orders for Meijer, Inc., Kerr Drug, Inc., Hy-Vee, Inc., and Fruth Pharmacy, Inc.
Additional information on the product may be found at www.GlucoseRapidSpray.com.
ADVERTISEMENT
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex |
